RxDoctor Payments Data

Roger Muse, MD

Clinical Cardiac Electrophysiology · San Antonio, TXNPI 1700885324

Payments from drug & device makers

$2,514in general payments, 2019–2025

Across 171 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$695
  • Boston Scientific$444
  • Novartis$427
  • Johnson & Johnson$307
  • Pfizer$98
  • Abiomed$79
  • plus $465 from 14 others

What the payments were for

  • Food & beverage$2,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,514 in reported general payments places this provider in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$257,855
Medicare patients
970
Services billed
4,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban844$821,979
XareltoRivaroxaban184$223,548
EntrestoSacubitril/Valsartan90$93,946
FarxigaDapagliflozin Propanediol71$53,137
Repatha SureclickEvolocumab24$23,480
Flecainide Acetate370$11,513
JardianceEmpagliflozin14$10,500
Praluent PenAlirocumab19$9,053
Propafenone Hcl ErPropafenone Hcl33$7,311
Amiodarone Hcl302$4,530
Metoprolol Succinate349$4,530
Lisinopril259$1,988
Bumetanide52$1,804
Potassium Chloride122$1,640
Carvedilol208$1,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$821,979844 claims
Johnson & JohnsonXarelto$307$223,548184 claims
NovartisEntresto$427$93,94690 claims
Boehringer IngelheimJardiance$17$10,50014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →